Vancogenx^®

Product code: 12A2520 (40g)

TAGS Medium Viscosity Gentamicin+Vancomycin

Features

Vancogenx^® is the medium viscosity bone cement loaded with Gentamicin and Vancomycin. Its medium viscosity makes it suitable for both syringe and manual applications. Antibiotics are released locally and is useful as a coadjuvant in the treatment of an infection. Available in the 40g pack.

Periprosthetic infections constitute one of the most critical post-operative complications in arthroplasty. The surface of the implant is a perfect environment for the adhesion and growth of bacteria. It is particularly difficult to treat infections due to MRSA (Methicillin-Resistant Staphylococcus aureus), MRSE (Methicillin-Resistant Staphylococcus epidermidis), and other resistant pathogens, which continue to represent a serious and widespread problem.

Vancogenx^® is the ideal bone cement for the fixation of antibiotic-loaded spacers during two-stage procedures in case of periprosthetic joint infection (PJI) and prosthetic components fixation during revision surgery following a septic process.

Benefits of Vancogenx^®

• Broad scpectrum of activity due to antibiotic synergy
• Effective as a coadjuvant in the treatment of an infection
• High and effective release of Vancomycin and Gentamicin
• Bacterial anti-adhesion thanks to the presence of antibiotics
• Approved for fixation of definitive revision prostheses
• Approved for cementation of antibiotic-loaded spacers

VANCOGENX®: Synergy

When combined, Gentamicin and Vancomycin have a synergistic action against bacteria.^1-2-3 Their range of action covers approximately 90% of the pathogenic agents generally isolated in surgical infections.^3-4 The Gentamicin and Vancomycin combination is the most commonly used and published combination in cases of concomitant treatment of orthopaedic infections. ^5-6-7

VANCOGENX^®: Effectiveness

Vancogenx^® bone cement has been shown to be able to prevent bacterial adhesion³ (in vitro tests) and as a coadjuvant in treatment of the infection (in vivo animal tests).⁸ In vitro studies have shown that Vancogenx^® exerts an anti-adhesion action by inhibiting bacterial proliferation. In vivo animal studies have proven Vancogenx®’s therapeutic efficacy in experimental osteomyelitis models. The results of the study indicate that local therapy with Vancogenx^® is able to eradicate infection and provides better results than systemic therapy with teicoplanin.⁸ Following surgical debridement, the local therapy achieved with Vancogenx^® eradicates infection and provides better results than systemic therapy.

Bibliography - 1. Watanakunakorn C, et al.Antimicrob Agents Chemother. 1973; 2. Watanakunakorn C, et al.Antimicrob Agents Chemother. 1982; 3. E. Bertazzoni Minelli, et al. Anaerobe. 2011; 4. Trampuz A, et al. Swiss Med Wkly. 2005; 5. Penner MJ, et al. J Arthroplasty. 1996; 6. Masri BA, et al. J Arthroplasty. 1998; 7. Bertazzoni Minelli E, et al. J Chemother. 2002; 8. Giavaresi G. et al. J Orthop Res. 2008